CytomX Therapeutics (CTMX) Price & Analysis

Compare

854 Followers

CTMX Stock Chart & Stats

$3.55

-$0.06(-5.83%)

At close: Jan 08 4:00 PM EST

$3.55

-$0.06(-5.83%)

Day’s Range― - ―

52-Week Range$0.40 - $4.62

Previous CloseN/A

Volume1.08M

Average Volume (3M)3.57M

Market Cap

$657.41M

Enterprise Value$388.33M

Total Cash (Recent Filing)$143.63M

Total Debt (Recent Filing)$5.60M

Price to Earnings (P/E)9.3

Beta2.79

Next Earnings

Mar 04, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding169,435,400

10 Day Avg. Volume5,305,654

30 Day Avg. Volume3,567,134

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-190.73

Price to Sales (P/S)0.63

P/FCF Ratio-1.00

Enterprise Value/Market Cap0.59

Enterprise Value/Revenue3.42

Enterprise Value/Gross Profit3.42

Enterprise Value/Ebitda14.87

Forecast

1Y Price Target

$6.50

Price Target Upside83.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)$87.58M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment for the CX-2051 Phase 1 trial has exceeded expectations, with ~100 patients to be enrolled, providing a stronger signal for an approval path.

Efficacy ResultsInitial CX-2051 data are tracking ahead of standard care product benchmarks, showing promising efficacy results.

Financial PerformanceCTMX reported no net loss or $0/share, above the estimate of ($0.14).

Bears Say

Analyst RatingThe analyst's neutral rating reflects the need for more de-risking data despite the potential of CX-2051.

Market ReactionThe market has already reacted to the development, with shares of CytomX down ~20% since the day prior to the press release.

Safety ConcernsThe company disclosed a grade 5 event of treatment-related acute kidney injury, which appears to be an isolated incident but still requires attention.

CytomX Therapeutics News

CytomX Therapeutics price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on CytomX Therapeutics (CTMX) to $10 from $5...

8d ago

CTMX

CytomX Therapeutics price target raised to $6.50 from $5 at Piper Sandler

Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $6.50 from $5 and keeps an...

9d ago

CTMX

CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)

Reports Q3 revenue $5.96M, consensus $11.5M. “CytomX continued to execute against its pipeline priorities this quarter, highlighted by...

12d ago

CTMX

CytomX Therapeutics management to meet with Oppenheimer

Meeting to be held on October 23-24 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

28d ago

CTMX

CytomX Therapeutics price target raised to $6 from $3.50 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $6 from $3.50 and...

29d ago

CTMX

CytomX Therapeutics appoints Rachael Lester as chief business officer

CytomX Therapeutics (CTMX) announced the appointment of Rachael Lester as senior VP, chief business officer. In this role,...

29d ago

CTMX

CytomX Therapeutics Earnings Call Highlights Clinical Progress

CytomX Therapeutics Inc. (($CTMX)) has held its Q3 earnings call. Read on for the main highlights of the...

10d ago

CTMX

CytomX Therapeutics Reports Q3 2025 Financial Results

CytomX Therapeutics Inc. ( ($CTMX) ) has released its Q3 earnings. Here is a breakdown of the information...

12d ago

CTMX

CytomX Therapeutics Advances CX-2051 Study in Solid Tumors

CytomX Therapeutics Inc. (($CTMX)) announced an update on their ongoing clinical study. Study Overview: CytomX Therapeutics Inc. is...

22d ago

CTMX

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on CTMX stock, giving a Hold rating on...

22d ago

CTMX

Oppenheimer positive on CytomX after Merus colon cancer data

Oppenheimer says Merus’ (MRUS) colon cancer data update reinforces its “enthusiasm” for CytomX Therapeutics’ (CTMX) dose expansion data....

1M ago

CTMX

MRUS

CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on CTMX stock, giving a Hold rating today....

2M ago

CTMX

CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target CytomX may...

2M ago

CTMX

CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target Published first...

2M ago

CTMX

CTMX FAQ

What was CytomX Therapeutics Inc’s price range in the past 12 months?

CytomX Therapeutics Inc lowest stock price was $0.40 and its highest was $4.62 in the past 12 months.

What is CytomX Therapeutics Inc’s market cap?

CytomX Therapeutics Inc’s market cap is $657.41M.

When is CytomX Therapeutics Inc’s upcoming earnings report date?

CytomX Therapeutics Inc’s upcoming earnings report date is Mar 04, 2026 which is in 105 days.

How were CytomX Therapeutics Inc’s earnings last quarter?

CytomX Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.049 by -$0.041.

Is CytomX Therapeutics Inc overvalued?

According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CytomX Therapeutics Inc pay dividends?

CytomX Therapeutics Inc does not currently pay dividends.

What is CytomX Therapeutics Inc’s EPS estimate?

CytomX Therapeutics Inc’s EPS estimate is -0.09.

How many shares outstanding does CytomX Therapeutics Inc have?

CytomX Therapeutics Inc has 169,435,400 shares outstanding.

What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?

CytomX Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.049. Following the earnings report the stock price went down -13.604%.

Which hedge fund is a major shareholder of CytomX Therapeutics Inc?

Currently, no hedge funds are holding shares in CTMX

CytomX Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

66.76%

Trailing 12-Months

Asset Growth

13.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CytomX Therapeutics Inc

CytomX Therapeutics (CTMX) is a biotechnology company focused on developing innovative cancer therapeutics based on its proprietary Probody platform. This platform enables the creation of targeted therapies that can selectively activate in the tumor microenvironment, thereby minimizing off-target effects and improving the safety and efficacy of cancer treatments. The company operates in the biopharmaceutical sector, primarily developing antibody-drug conjugates (ADCs) and other targeted therapies for various types of cancer.

CytomX Therapeutics (CTMX) Earnings & Revenues

Historic Earnings Reports

CTMX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment with strong clinical progress and strategic advancements in key programs, despite a decrease in revenue and some adverse events in trials.View all CTMX earnings summaries

CTMX Stock 12 Month Forecast

Average Price Target

$6.50

▲(83.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,4.064615384615385,4.559230769230769,5.053846153846154,5.548461538461538,6.043076923076923,6.537692307692307,7.0323076923076915,7.526923076923076,8.02153846153846,8.516153846153845,9.01076923076923,9.505384615384616,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.795384615384615,4.020769230769231,4.246153846153846,4.4715384615384615,4.696923076923077,4.922307692307692,5.147692307692308,5.373076923076923,5.598461538461539,5.823846153846153,6.049230769230769,6.274615384615385,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.5646153846153843,3.559230769230769,3.5538461538461537,3.5484615384615386,3.543076923076923,3.5376923076923075,3.5323076923076924,3.526923076923077,3.5215384615384613,3.516153846153846,3.5107692307692306,3.5053846153846155,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >